AB Sciex Debuts Two Mass Spectrometry–Based Devices for Clinical Dx

AB Sciex has introduced two clinical diagnostic devices for analyzing trace levels of multiple compounds in human samples. Called API 3200MD and 3200MD QTRAP, the devices use LC/MS/MS techniques for identifying organic or inorganic compounds. The mass spectrometry–based systems are the first in a series of 3200MD IVD products that AB Sciex plans to introduce worldwide, the company says.
Rainier Blair, president of AB Sciex, calls clinical diagnostics “the new frontier for mass spectrometry.” In 2012 the Framingham, MA–based company announced that it had received ISO 13485:2003 certification, the quality management standard for manufacturing medical devices. On February 6, 2013, AB Sciex also announced the signing of a multi-year agreement with the Institute of Systems Biology (ISB) in Seattle to collaborate on the development of technology in proteomics mass spectrometry. The partners are looking to develop comprehensive quantitative proteomics analysis for biomarker and genomics research. ISB will use the TripleTOF 5600 and Eksigent ekspert nano-LC 400 systems from AB Sciex as the instrument platforms for protein identification and quantitation.
The partnership is through the AB Sciex Academic Partnership Program. ISB has developed the concept of P4 medicine, meaning healthcare that is predictive, personalized, preventive, and participatory. The institute’s research is rooted in a data-independent acquisition mass spectrometry technology. Called SWATH Acquisition, the workflow technology is able to quantify almost all detectable peptides and proteins in a complex sample in one single analysis, according to ISB.
–John Conroy